A5007209469- Lymphoma Diagnosis and Treatment
- Viral-associated cancers and disorders
- Immune Cell Function and Interaction
- Monoclonal and Polyclonal Antibodies Research
- Radiopharmaceutical Chemistry and Applications
- CAR-T cell therapy research
- T-cell and Retrovirus Studies
- Cytomegalovirus and herpesvirus research
- RNA regulation and disease
- Synthesis and Biological Evaluation
- Eosinophilic Disorders and Syndromes
- Cancer therapeutics and mechanisms
- Immunotherapy and Immune Responses
- Immunodeficiency and Autoimmune Disorders
- NF-κB Signaling Pathways
- Zoonotic diseases and public health
- Autoimmune and Inflammatory Disorders
- Multiple Myeloma Research and Treatments
- T-cell and B-cell Immunology
- Biomedical Text Mining and Ontologies
Inserm
2019-2022
Université de Limoges
2009-2022
Contrôle de la Réponse Immune B et Lymphoproliférations
2019-2022
Centre National de la Recherche Scientifique
2010-2021
Hôpital Dupuytren
2010-2013
Hôpital Universitaire Dupuytren
2009
The Epstein-Barr virus (EBV) latency III program imposed by EBNA2 and LMP1 is directly responsible for immortalization of B cells in vitro thought to mediate most immunodeficiency-related posttransplant lymphoproliferative diseases vivo. To answer the question whether how this proliferation related c-Myc, we have established transcriptome both c-Myc EBV programs using a Lymphochip specialized microarray. In addition EBV-positive I Burkitt lymphoma lines lymphoblastoid cell (LCLs), used an...
Multiple myeloma (MM) is a plasma cell cancer and represents the second most frequent hematologic malignancy. Despite new treatments protocols, including high-dose chemotherapy associated with autologous stem transplantation, prognosis of MM patients still poor. α-radioimmunotherapy (α-RIT) an attractive treatment strategy because high-linear-energy transfer short pathlength α-radiation in tissues, resulting high tumor killing low toxicity to surrounding tissues. In this study, we...
EBV-immortalized B cells induce a complex immune response such that the virus persists as clinically silent infection for lifetime of infected host. B7-H1, also called PD-L1, is cosignaling molecule B7 family can inhibit activated T cell effectors by interaction with its receptor PD-1. In this work, we have studied dependence B7-H1 on NF-κB and c-Myc, two main transcription factors in EBV latency III proliferating cells, various lymphoblastoid Burkitt lymphoma lines, some them being...
Upregulated expression of the anti-apoptotic BCL2 oncogene is a common feature various types B-cell malignancies, from lymphoma to leukemia or myeloma. It currently unclear how patterns deregulation observed in pathology eventually impact phenotype malignant B cells and their microenvironment. Follicular (FL) most non-Hodgkin arising germinal center (GC) B-cells, its major hallmark t(14:18) translocation occurring cell progenitors placing gene under control immunoglobulin heavy chain locus...
BISCEm (https://www.unilim.fr/biscem/), acronyme de Biologie Intégrative Santé Chimie Environnement, est une plateforme technologique créée par l’Institut recherche GEIST en 2017. La regroupe des équipements pointe permettant la réalisation d’analyses moléculaires, cellulaires et tissulaires d’expériences sur animaux, dans le strict respect règlementation vigueur du bien-être animal. prestations, formation à l’utilisation équipements, les conseils conception expériences l’interprétation...
Abstract Follicular lymphoma (FL) is the most common indolent form of non-Hodgkin arising from malignant germinal center (GC) B-cells. The genetic hallmark that leads to development FL t(14:18) which occurs early in bone marrow during B cell development, thereby placing anti-apoptotic BCL2 gene under direct control transcriptional enhancers 3’ immunoglobulin heavy chain locus (IgH 3’RR) and leading constitutive expression protein. To assess impact deregulation on B-cell fate try reproduce...